Group 1 - The core viewpoint of the report is that with a significant amount of fixed deposits maturing next year, insurance is seen as a favorable option for low-risk investors seeking long-term wealth preservation and appreciation, with clearer growth expectations for liabilities [1] - The brokerage sector is experiencing a notable divergence between performance and valuation, with industry profits maintaining high growth while stock prices and valuations remain under pressure, leading to a price-to-book (PB) ratio of 1.35, which is at the 33rd percentile over the past decade [1] - The report suggests that as brokerage mergers progress and international business layouts deepen, there is substantial room for performance recovery among undervalued leading brokerages, making them increasingly attractive for investment [1] Group 2 - Investment recommendations focus on three main lines: (1) brokerage firms with third-quarter earnings exceeding expectations, particularly those with a PB of only 1.35x, such as Guotai Junan and Haitong Securities; (2) Sichuan Shuangma, which is positioned well in the technology sector and is expected to benefit from venture capital in the gene therapy space; (3) multi-financial firms with impressive growth rates, particularly the Hong Kong Stock Exchange, which will continue to benefit from deepening connectivity and increased trading activity [2] - The new group health insurance in Shanghai, expected to launch in December, will include over 80 high-value innovative drugs, providing a significant opportunity for commercial health insurance products to cover innovative drug payments, potentially generating sales of 500 million to 1 billion yuan annually [3] - The insurance sector is anticipated to see a double-digit growth in new policy premiums, with new products expected to provide better value due to interest margin benefits, particularly through the bancassurance channel [4]